DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fw74w3/pharmapoint) has announced the addition of the "PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023" report to their offering.
Prostate Cancer Treatment Market Value Will Treble to $8.2 Billion by 2023
The global treatment market value for prostate cancer, excluding hormonal and bone therapies, will expand more than threefold from $2.6 billion in 2013 to an estimated $8.2 billion by 2023, according to research and consulting firm The authors.
The company's latest report states that this increase, which will occur across the nine major markets (9MM) of the US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada, will be driven by a rapidly aging population, the introduction of nine new, premium-priced therapies by 2023, and the expected label extensions for both Zytiga and Xtandi in the treatment of hormone-sensitive prostate cancer.
Furthermore, Raksha Mudbhary, Ph.D., The authors's Senior Analyst covering Oncology, says that Japan and Brazil will experience particularly impressive market growth during the forecast period, due to the increased screening of prostate cancer resulting in higher incidence in Japan, as well as the introduction of several branded products for the treatment of castration-resistant prostate cancer (CRPC).
However, the analyst notes that the primary driver of growth across the 9MM for prostate cancer treatment will be the label extension of Xtandi into chemotherapy-naïve metastatic CRPC, non-metastatic CRPC and hormone-sensitive prostate cancer.
Mudbhary explains: Xtandi's safety and efficacy garnered a favorable impression from Key Opinion Leaders, and its use in multiple prostate cancer patient segments ensures that it will be the market-leading drug in this therapy area by 2016.
The authors forecasts that sales of Xtandi will grow to $3.8 billion by 2023, at a CAGR of 24%, accounting for an impressive 46% of total branded drug sales in the prostate cancer space.
Despite the positive outlook over the forecast period, a few factors may limit growth, primarily the loss of patent protection for Zytiga, the leading drug in the prostate cancer therapeutics market in 2013.
The analyst continues: Zytiga is anticipated to lose key US patent protection in December 2016. Although there is some uncertainty regarding the timing of Zytiga generics entering the US market, the resulting loss of branded sales will restrict growth during the latter part of the forecast period.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Unmet Need and Opportunity
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
- Johnson & Johnson
For more information visit http://www.researchandmarkets.com/research/fw74w3/pharmapoint.